Author

C. Schultheiss

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:CITE-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

M. Binder· 4 shared L. Paschold· 3 shared D. Simnica· 2 shared A. Cardon· 1 shared A. Domene· 1 shared A. Fasano· 1 shared A. Holtermann· 1 shared A. Imbert· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Binder

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The immune profile of circulating autoreactive CD4 T cells is imprinted through tissue activation during autoimmune liver diseases

A. Cardon, T. Guinebretiere, C. Dong, L. Gil, S. Ado, P.-j. Gavlovsky, M. Braud, R. Danger, C. Schultheiss, A. Domene, P. Paul-Gilloteaux, C. Chevalier, L. Bernier, J.-P. Judor, C. Fourgeux, , A. Renand

This study identifies the transcriptional profile of circulating autoreactive CD4 T cells in autoimmune liver diseases and shows their functional relationship to liver-specific pathogenic clones.

bioRxiv · Mar 26, 2024Immunology

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

F. Maerkl, C. Schultheiss, M. Ali, S.-S. Chen, L. Egli, J. Mietz, O. Chijoke, L. Paschold, S. Spajic, A. Holtermann, J. Doerr, S. Stock, I. Piseddu, D. Anz, M. Duehren-von Minden, , M. Binder

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.

bioRxiv · Sep 29, 2023 · PreprintCancer Biology

Rapid hypermutation B cell trajectory recruits previously primed B cells upon third SARS-CoV-2 mRNA vaccination

L. Paschold, B. Klee, C. Gottschick, E. Willscher, S. Diexer, C. Schultheiss, D. Simnica, D. Sedding, M. Girndt, M. Gekle, R. Mikolajczyk, M. Binder

The paper tracks SARS-CoV-2 B cell hypermutation levels across vaccinations, showing increased somatic hypermutation after the third dose, which may explain better protection against variants like Omicron.

bioRxiv · Mar 1, 2022Immunology

Identification of a unique TCR repertoire, consistent with a superantigen selection process in Children with Multi-system Inflammatory Syndrome

R. A. Porritt, L. Paschold, M. Noval Rivas, M. H. Cheng, L. M. Yonker, H. Chandnani, M. Lopez, D. Simnica, C. Schultheiss, C. Santiskulvong, J. Van Eyk, A. Fasano, I. Bahar, M. Binder, M. Arditi

This study identifies a skewed TCR repertoire in MIS-C patients, with TRBV11-2 expansion linked to disease severity and superantigen-like interactions with SARS-CoV-2 spike protein.

bioRxiv · Nov 9, 2020 · PreprintImmunology